Consulting Services
For Investors
Products
Case Studies
Insights
BioPharma and Tech News

Contact Us

Search

Heart Failure Society of America

Artificial_Intelligence

AI in Healthcare and Digital Health Video Recap—February 9, 2026

This biweekly AI in Healthcare and Digital Health video recap covers major…

by Timos Papagatsias

Artificial_Intelligence

AI in Healthcare and Digital Health Today—February 2, 2026

This week's AI in Healthcare and Digital Health update highlights AI’s…

by Timos Papagatsias

Categories

Obesity News
Endocrinology News
Our Insights
Immunology News
Case studies
Hematology News
BioPharma and Tech News
Oncology News
BioPharma Strategy, CI and AI Guides
Lucid Diligence Brief
Conference Social Media Reports
Venture Capital Trends
AI in Healthcare and Digital Health
Conference Previews
Cell and Gene Therapy News
Healthcare and Pharma Trends
Rare Disease News
Health Mobile Apps Reports
Neuroscience News
Women's Health News
Public Health News
Respiratory News
Cardiovascular News
Vaccine news

Recent Posts

Lucid Diligence Brief: Fauna Bio obesity target designation with Lilly
Lucid Diligence Brief: Novartis to acquire Pikavation Therapeutics from Synnovation
Public Health Today—March 20, 2026
Vaccines Today—March 20, 2026
Respiratory Today—March 20, 2026

Tags

Behcet’s disease Bio-Thera Bivamelagon Blackstone Life Sciences Cardiac Rehab Cardiovascular Risk Casgevy chronic disease prevention Competitive Intelligence Process Copper histidinate Desmopressin Duchenne MD ESC2025 Ethionamide Exosome Vaccines France SNDS GLP1 drugs Great Ormond Street Hospital Haemonetics healthcare tech IgG4 Related Disease immunometabolism KRAS KRAS mutation Macular degeneration Mantle Cell Lymphoma med tech Metformin Microplastics Nutrition Science OTTAVA robotic surgical system Parathyroid hormone–based therapies patient monitoring pediatric rare disease Phase 1b clinical trials robotic surgery Royalty Pharma RRMS SciNeuro Shanghai Jiao Tong University Sjögrens Disease Sunlenca translational medicine TULIP-SC Trial Type 3 Gaucher disease

Archives

Archives

LucidQuest Ventures

Accelerate Your Success

LATEST NEWS

Lucid Diligence Brief: Fauna Bio obesity target designation with Lilly
Lucid Diligence Brief: Novartis to acquire Pikavation Therapeutics from Synnovation
Public Health Today—March 20, 2026
Vaccines Today—March 20, 2026
Respiratory Today—March 20, 2026

TAGS

Behcet’s disease Bio-Thera Bivamelagon Blackstone Life Sciences Cardiac Rehab Cardiovascular Risk Casgevy chronic disease prevention Competitive Intelligence Process Copper histidinate Desmopressin Duchenne MD ESC2025 Ethionamide Exosome Vaccines France SNDS GLP1 drugs Great Ormond Street Hospital Haemonetics healthcare tech IgG4 Related Disease immunometabolism KRAS KRAS mutation Macular degeneration Mantle Cell Lymphoma med tech Metformin Microplastics Nutrition Science OTTAVA robotic surgical system Parathyroid hormone–based therapies patient monitoring pediatric rare disease Phase 1b clinical trials robotic surgery Royalty Pharma RRMS SciNeuro Shanghai Jiao Tong University Sjögrens Disease Sunlenca translational medicine TULIP-SC Trial Type 3 Gaucher disease

Consulting Services
For Investors
Products
Case Studies
Insights
BioPharma and Tech News

© 2026 LucidQuest Ventures. All rights reserved

We use cookies from third party services to offer you a better experience. Read about how we use cookies and how you can control them by clicking "Privacy Preferences".

Privacy Preference Center

Privacy Preferences

When you visit any website, it may store or retrieve information on your browser in the form of cookies. Since we respect your right to privacy, you can choose not to permit data collection from certain types of services. However, not allowing these services may impact your experience ans we are able to offer you.

Privacy Policy

Required

You read and agreed to our Privacy Policy

Tracking

We use third-party cookies that help us analyze and understand how you use this website. These cookies do not store any personal information.

Privacy Policy